GeneOne Life Science Inc (011000) — Cash Flow-to-Debt Ratio
GeneOne Life Science Inc (011000) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2025, meaning its operating cash flow of ₩-1.77 Billion could theoretically repay 0% of its total liabilities (₩78.31 Billion) in one year. See 011000 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GeneOne Life Science Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for GeneOne Life Science Inc across 13 annual periods. Also explore 011000 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for GeneOne Life Science Inc (2013–2025)
Year-by-year debt coverage analysis for GeneOne Life Science Inc. For market capitalisation and broader financial context, see GeneOne Life Science Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.54 Billion | ₩78.31 Billion | ▲ +13.5% |
| 2024 | -0.24x | ₩-16.06 Billion | ₩65.73 Billion | ▲ +55.6% |
| 2023 | -0.55x | ₩-21.74 Billion | ₩39.52 Billion | ▲ +5.5% |
| 2022 | -0.58x | ₩-24.11 Billion | ₩41.40 Billion | ▼ -429.0% |
| 2021 | -0.11x | ₩-4.85 Billion | ₩44.04 Billion | ▲ +73.7% |
| 2020 | -0.42x | ₩-15.92 Billion | ₩38.06 Billion | ▼ -792.0% |
| 2019 | -0.05x | ₩-1.27 Billion | ₩27.09 Billion | ▲ +87.2% |
| 2018 | -0.37x | ₩-7.27 Billion | ₩19.89 Billion | ▲ +17.7% |
| 2017 | -0.44x | ₩-4.04 Billion | ₩9.09 Billion | ▼ -6.9% |
| 2016 | -0.42x | ₩-12.39 Billion | ₩29.81 Billion | ▼ -540.5% |
| 2015 | 0.09x | ₩778.50 Million | ₩8.25 Billion | ▲ +113.7% |
| 2014 | -0.69x | ₩-4.16 Billion | ₩6.03 Billion | ▼ -138.1% |
| 2013 | -0.29x | ₩-2.35 Billion | ₩8.11 Billion | — |